Skip to content

Free cash flow at other companies

IQVIA logo
IQVIAIQV
$491M+15.3%
Labcorp Holdings logo
Labcorp HoldingsLH
Revvity logo
RevvityRVTY
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
TEC
Bio-TechneTECH

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-4.6%
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%
Debt / equity+0.1×
Current ratio1.4×-0.1×

Where this comes from

Calculated from Charles River Laboratories’s reported figures.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's free cash flow?
Charles River Laboratories (CRL) reported free cash flow of -$14.83M in Q1 2026.
How has Charles River Laboratories's free cash flow changed year-over-year?
Charles River Laboratories's free cash flow decreased by 113.2% year-over-year, from $112.37M to -$14.83M.
What is the long-term trend for Charles River Laboratories's free cash flow?
Over 4 years (2021 to 2025), Charles River Laboratories's free cash flow has grown at a -0.6% compound annual growth rate (CAGR), from $532.03M to $518.49M.